Format

Send to

Choose Destination
Oncotarget. 2016 Apr 26;7(17):23251-62. doi: 10.18632/oncotarget.8136.

Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.

Author information

1
Department of Pathology, Singapore General Hospital, Singapore.
2
Department of Medical Oncology, National Cancer Center Singapore, Singapore.
3
Department of Molecular Oncology, National University Health System Singapore, Singapore.
4
Faculty of Engineering, Department of Biomedical Engineering, National University of Singapore, Singapore.
5
Mechanobiology Institute, National University of Singapore, Singapore.
6
Clearbridge Biomedics Pte Ltd., Singapore.
7
Institute of Molecular and Cell Biology, Singapore.

Abstract

Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC) is routinely evaluated by fluorescent in-situ hybridization (FISH) testing on biopsy tissues. Testing can be challenging however, when suitable tissue samples are unavailable. We examined the relevance of circulating tumor cells (CTC) as a surrogate for biopsy-based FISH testing. We assessed paired tumor and CTC samples from patients with ALK rearranged lung cancer (n = 14), ALK-negative lung cancer (n = 12), and healthy controls (n = 5) to derive discriminant CTC counts, and to compare ALK rearrangement patterns. Blood samples were enriched for CTCs to be used for ALK FISH testing. ALK-positive CTCs counts were higher in ALK-positive NSCLC patients (3-15 cells/1.88 mL of blood) compared with ALK-negative NSCLC patients and healthy donors (0-2 cells/1.88 mL of blood). The latter range was validated as the 'false positive' cutoff for ALK FISH testing of CTCs. ALK FISH signal patterns observed on tumor biopsies were recapitulated in CTCs in all cases. Sequential CTC counts in an index case of lung cancer with no evaluable tumor tissue treated with crizotinib showed six, three and eleven ALK-positive CTCs per 1.88 mL blood at baseline, partial response and post-progression time points, respectively. Furthermore, ALK FISH rearrangement suggestive of gene copy number increase was observed in CTCs following progression. Recapitulation of ALK rearrangement patterns in the tumor on CTCs, suggested that CTCs might be used to complement tissue-based ALK testing in NSCLC to guide ALK-targeted therapy when suitable tissue biopsy samples are unavailable for testing.

KEYWORDS:

ALK-gene rearrangement; circulating tumor cells; fluorescent in-situ hybridization; lung cancer; molecular diagnosis

PMID:
26993609
PMCID:
PMC5029624
DOI:
10.18632/oncotarget.8136
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center